For example, nutlins, cis-imidazoline analogs able to inhibit the interaction between MDM2 and tumor suppressor p53, have recently entered early clinical trials for the treatment of blood cancers (Burgess et al., 2016). This evidence concerns the gene MDM2 and hematopoietic and lymphoid system neoplasm.